UNLABELLED: Tariquidar, a potent, nontoxic, third-generation P-glycoprotein (P-gp) inhibitor, is a possible reversal agent for central nervous system drug resistance. In animal studies, tariquidar has been shown to increase the delivery of P-gp substrates into the brain by severalfold. The aim of this study was to measure P-gp function at the human blood-brain barrier (BBB) after tariquidar administration using PET and the model P-gp substrate (R)-(11)C-verapamil. METHODS: Five healthy volunteers underwent paired (R)-(11)C-verapamil PET scans and arterial blood sampling before and at 2 h 50 min after intravenous administration of tariquidar (2 mg/kg of body weight). The inhibition of P-gp on CD56-positive peripheral lymphocytes of each volunteer was determined by means of the (123)Rh efflux assay. Tariquidar concentrations in venous plasma were quantified using liquid chromatography/mass spectrometry. RESULTS: Tariquidar administration resulted in significant increases (Wilcoxon test for paired samples) in the distribution volume (DV, +24% +/- 15%) and influx rate constant (K(1), +49% +/- 36%) of (R)-(11)C-verapamil across the BBB (DV, 0.65 +/- 0.13 and 0.80 +/- 0.07, P = 0.043; K(1), 0.034 +/- 0.009 and 0.049 +/- 0.009, P = 0.043, before and after tariquidar administration, respectively). A strong correlation was observed between the change in brain DV after administration of tariquidar and tariquidar exposure in plasma (r = 0.90, P = 0.037). The mean plasma concentration of tariquidar achieved during the second PET scan (490 +/- 166 ng/mL) corresponded to 100% inhibition of P-gp function in peripheral lymphocytes. CONCLUSION: Tariquidar significantly increased brain penetration of (R)-(11)C-verapamil-derived activity due to increased influx. As opposed to peripheral P-gp function, central P-gp inhibition appeared to be far from complete after the administered tariquidar dose.
UNLABELLED: Tariquidar, a potent, nontoxic, third-generation P-glycoprotein (P-gp) inhibitor, is a possible reversal agent for central nervous system drug resistance. In animal studies, tariquidar has been shown to increase the delivery of P-gp substrates into the brain by severalfold. The aim of this study was to measure P-gp function at the human blood-brain barrier (BBB) after tariquidar administration using PET and the model P-gp substrate (R)-(11)C-verapamil. METHODS: Five healthy volunteers underwent paired (R)-(11)C-verapamil PET scans and arterial blood sampling before and at 2 h 50 min after intravenous administration of tariquidar (2 mg/kg of body weight). The inhibition of P-gp on CD56-positive peripheral lymphocytes of each volunteer was determined by means of the (123)Rh efflux assay. Tariquidar concentrations in venous plasma were quantified using liquid chromatography/mass spectrometry. RESULTS:Tariquidar administration resulted in significant increases (Wilcoxon test for paired samples) in the distribution volume (DV, +24% +/- 15%) and influx rate constant (K(1), +49% +/- 36%) of (R)-(11)C-verapamil across the BBB (DV, 0.65 +/- 0.13 and 0.80 +/- 0.07, P = 0.043; K(1), 0.034 +/- 0.009 and 0.049 +/- 0.009, P = 0.043, before and after tariquidar administration, respectively). A strong correlation was observed between the change in brain DV after administration of tariquidar and tariquidar exposure in plasma (r = 0.90, P = 0.037). The mean plasma concentration of tariquidar achieved during the second PET scan (490 +/- 166 ng/mL) corresponded to 100% inhibition of P-gp function in peripheral lymphocytes. CONCLUSION:Tariquidar significantly increased brain penetration of (R)-(11)C-verapamil-derived activity due to increased influx. As opposed to peripheral P-gp function, central P-gp inhibition appeared to be far from complete after the administered tariquidar dose.
Authors: Mark Lubberink; Gert Luurtsema; Bart N M van Berckel; Ronald Boellaard; Rolf Toornvliet; Albert D Windhorst; Eric J F Franssen; Adriaan A Lammertsma Journal: J Cereb Blood Flow Metab Date: 2006-06-07 Impact factor: 6.200
Authors: Jeih-San Liow; William Kreisl; Sami S Zoghbi; Neva Lazarova; Nicholas Seneca; Robert L Gladding; Andrew Taku; Peter Herscovitch; Victor W Pike; Robert B Innis Journal: J Nucl Med Date: 2008-12-17 Impact factor: 10.057
Authors: Daniel Kurnik; Gbenga G Sofowora; John P Donahue; Usha B Nair; Grant R Wilkinson; Alastair J J Wood; Mordechai Muszkat Journal: Anesthesiology Date: 2008-12 Impact factor: 7.892
Authors: Jens P Bankstahl; Claudia Kuntner; Aiman Abrahim; Rudolf Karch; Johann Stanek; Thomas Wanek; Wolfgang Wadsak; Kurt Kletter; Markus Müller; Wolfgang Löscher; Oliver Langer Journal: J Nucl Med Date: 2008-07-16 Impact factor: 10.057
Authors: Aiman Abrahim; Gert Luurtsema; Martin Bauer; Rudolf Karch; Mark Lubberink; Ekaterina Pataraia; Christian Joukhadar; Kurt Kletter; Adriaan A Lammertsma; Christoph Baumgartner; Markus Müller; Oliver Langer Journal: Eur J Nucl Med Mol Imaging Date: 2007-09-11 Impact factor: 9.236
Authors: Oliver Langer; Martin Bauer; Alexander Hammers; Rudolf Karch; Ekaterina Pataraia; Matthias J Koepp; Aiman Abrahim; Gert Luurtsema; Martin Brunner; Raute Sunder-Plassmann; Friedrich Zimprich; Christian Joukhadar; Stephan Gentzsch; Robert Dudczak; Kurt Kletter; Markus Müller; Christoph Baumgartner Journal: Epilepsia Date: 2007-05-01 Impact factor: 5.864
Authors: M Bauer; M Zeitlinger; R Karch; P Matzneller; J Stanek; W Jäger; M Böhmdorfer; W Wadsak; M Mitterhauser; J P Bankstahl; W Löscher; M Koepp; C Kuntner; M Müller; Oliver Langer Journal: Clin Pharmacol Ther Date: 2011-12-14 Impact factor: 6.875
Authors: Eduardo R Butelman; Michael Caspers; Kimberly M Lovell; Mary Jeanne Kreek; Thomas E Prisinzano Journal: J Pharmacol Exp Ther Date: 2012-03-20 Impact factor: 4.030
Authors: Florian Bauer; Claudia Kuntner; Jens P Bankstahl; Thomas Wanek; Marion Bankstahl; Johann Stanek; Severin Mairinger; Bernd Dörner; Wolfgang Löscher; Markus Müller; Thomas Erker; Oliver Langer Journal: Bioorg Med Chem Date: 2010-06-22 Impact factor: 3.641
Authors: Martin Bauer; Rudolf Karch; Friederike Neumann; Claudia C Wagner; Kurt Kletter; Markus Müller; Wolfgang Löscher; Markus Zeitlinger; Oliver Langer Journal: J Cereb Blood Flow Metab Date: 2009-12-16 Impact factor: 6.200
Authors: Claudia Kuntner; Jens P Bankstahl; Marion Bankstahl; Johann Stanek; Thomas Wanek; Gloria Stundner; Rudolf Karch; Rebecca Brauner; Martin Meier; Xiaoqi Ding; Markus Müller; Wolfgang Löscher; Oliver Langer Journal: Eur J Nucl Med Mol Imaging Date: 2009-12-17 Impact factor: 9.236
Authors: Viktoria Zoufal; Thomas Wanek; Markus Krohn; Severin Mairinger; Thomas Filip; Michael Sauberer; Johann Stanek; Thomas Pekar; Martin Bauer; Jens Pahnke; Oliver Langer Journal: J Cereb Blood Flow Metab Date: 2018-10-24 Impact factor: 6.200